
Human Lymphocyte antigen 6K 119-128, RYCNLEGPPI
Description
About Human Lymphocyte antigen 6K 119-128, RYCNLEGPPI
The Human Lymphocyte antigen 6K Peptide (IEDB: 767706) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Lymphocyte antigen 6K Peptide, H-RYCNLEGPPI-OH (Uniprot: Q17RY6 aa: 119-128) from JPT is produced under strict quality control and quality management.
Human Lymphocyte antigen 6K 119-128, RYCNLEGPPI - Specifications
- Peptide sequence: H-RYCNLEGPPI-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Lung cancer, Melanoma, Adenocarcinoma, Gastric cancer, Cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Lymphocyte antigen 6K 119-128, RYCNLEGPPI
References:
Read References with JPT’s Antigen Peptides
Human Lymphocyte antigen 6K 119-128, RYCNLEGPPI has been described in:
Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination., Cancer Immunol Immunother, 2018 (PMID: 29568993)
Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma., Elife, 2020 (PMID: 32314731)
Documentation
Documentation for Human Lymphocyte antigen 6K 119-128, RYCNLEGPPI
Properties
Properties of Human Lymphocyte antigen 6K 119-128, RYCNLEGPPI
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Adenocarcinoma, Cancer, Gastric cancer, Lung cancer, Melanoma |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Lymphocyte antigen 6K 119-128, RYCNLEGPPI
Information | Values |
---|---|
Sequence: | H-RYCNLEGPPI-OH |
Specifications: | 10mer peptide as TFA salt |